Omeprazole Market, By Dosage Form (Capsule, Powder, and Tablet), By Indication (Duodenal Ulcer, Gastric Ulcer, Gastroesophageal Reflux Disease (GERD), Erosive Esophagitis, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)
Omeprazole Market Size and Share Analysis: (2026-2033)
The Omeprazole Market size is anticipated to grow at a CAGR of 3.9% with USD 7.4 Bn in 2026 and is expected to reach USD 9.67 Bn in 2033. The primary drivers are defined by increasing prevalence of gastrointestinal disorders such as gastroesophageal reflux disease (GERD), duodenal ulcers, and gastric ulcers across hospitals, clinics, and outpatient care facilities. Some of the other factors include rising awareness of digestive health, growth in prescription and OTC usage, ongoing generic drug approvals, and preference for proton pump inhibitors due to their efficacy and safety profile. According to the American College of Gastroenterology, around 20% of the U.S. population has GERD, reinforcing the demand for Omeprazole therapy.
Key Takeaways:
The tablets segment is likely to dominate the market with 45.2% in 2026. The segment’s growth is owing to its widespread use in chronic acid‑related conditions, patient preference for easy‑to‑take formulations, and broad inclusion in standard treatment protocols. About 60% of the U.S. adults reported taking at least one prescription medication in the past 12 months, and 36% took three or more, thereby indicating broad reliance on chronic therapies which include acid suppressants.
The Gastroesophageal Reflux Disease (GERD) segment is set to lead with 52.8% in 2026. The segment’s growth is owing to the increasing prevalence of acid reflux disorders and strong clinical recommendation for proton pump inhibitors (PPIs) like omeprazole as first‑line therapy in persistent GERD. The global data showed that GERD cases continued to rise, with an estimated 825.6, thereby indicating a substantial and growing patient population likely to use PPIs.
The retail pharmacies segment is set to lead with 36.4% in 2026. The segment’s growth is owing to the easy over‑the‑counter availability of omeprazole in many markets, strong pharmacy networks, and preference for convenient outpatient refills for ongoing acid suppression therapy.
Asia Pacific is expected to acquire the prominent share of 37.50% in 2026. The region’s growth is owing to the rising GERD burden linked to urbanization, dietary changes, and healthcare access expansion, which supports greater diagnosis and treatment uptake. The global burden data showed East Asia recorded over 396 million new instances of GERD, accounting for about 12.2% of global new GERD cases, thereby highlighting a substantial regional disease activity that supports the demand for acid‑suppressing medications.
The tablets segment is projected to account for the largest Omeprazole Market share of 45.2% in 2026. The segment’s growth is owing to its suitability for over-the-counter heartburn treatment, dose convenience, and patient-friendly administration.
Official DailyMed labeling for omeprazole delayed-release tablets states that adults 18 years and older should take one tablet once daily for a 14-day course, supporting standardized consumer use and repeat retail demand. The label also notes that the 20 mg delayed-release tablet may take 1 to 4 days for full effect, positioning tablets for planned, course-based therapy rather than immediate episodic relief.
In August 2025, Marksans Pharma Limited’s wholly owned subsidiary, Marksans Pharma Inc., received USFDA approval for Omeprazole Delayed-Release Tablets, 20 mg (OTC), enhancing domestic availability and consumer access.
Gastroesophageal Reflux Disease (GERD) hold the Largest Market Share
On the basis of indication, the Gastroesophageal Reflux Disease (GERD) segment lead with a major 52.8% share in 2026. The growth is owing to the escalating global prevalence of chronic acid-related gastrointestinal conditions, heavily impacting prescription trends.
According to the official data from the Drug Usage Statistics, the omeprazole ranks as the 9th most commonly prescribed medication in the United States and accounts for more than 54.5 million annual prescriptions.
In March 2021, Xiromed LLC, the New Jersey-based generic division of Insud Pharmaceuticals, launched Omeprazole Delayed-Release Capsules, 20 mg, as a generic equivalent to Prilosec. The product targets treatment of duodenal and gastric ulcers, GERD, and maintenance of healing of erosive esophagitis, thereby reinforcing cost-effective generic options in the U.S. omeprazole market.
Market Drivers
Rising Prevalence of Acid ‑Related Disorders is Transforming the Omeprazole Market in the US
The rising prevalence of acid-related gastrointestinal conditions like gastroesophageal reflux disease (GERD) and peptic ulcers is driving substantial growth in the U.S. omeprazole market.
According to the official records from the National Institutes of Health, omeprazole is one of the most widely prescribed therapies in the country, with over 45 million prescriptions annually. The FDA Adverse Event Reporting System (FAERS) further highlights domestic demand, thereby showing that the U.S. accounts for 55.67% of global safety monitoring and utilization reports for this proton pump inhibitor.
To meet this growing need, the domestic manufacturing pipelines are expanding, thereby ensuring consistent supply across retail as well as healthcare channels. In October 2024, PL Developments secured the FDA approval for its Abbreviated New Drug Application (ANDA) for Omeprazole Magnesium Tablets. This makes it the sole U.S.-based manufacturer supplying the over-the-counter market.
Expanded Delivery Formats and Patient ‑Centric Versions: A Major Breakthrough in the Omeprazole Market
The push toward more adaptable, patient-centric versions is heavily propelling the clinical trial pipelines, specifically targeting vulnerable patient populations that struggle with conventional oral formats. To optimize therapeutic delivery, the researchers are actively looking beyond standard delayed-release tablets.
For instance, the active clinical trial protocol detailed on the ClinicalTrials.gov highlights critical pharmacokinetic and pharmacodynamic optimization using alternative rectal suppository formulations of omeprazole. This delivery format targets infants aged 0–12 months who are suffering from severe gastroesophageal reflux disease (GERD), a demographic where standard oral doses are highly unpredictable.
The comprehensive FDA Adverse Event Reporting System (FAERS) data indicates that the gender-specific utilization patterns remain highly visible, with females representing 59.34% of all tracked therapeutic issues and side effects associated with the drug. This underlines a growing clinical demand for tailored dosage strengths. These precise demographic tracking statistics, combined with specialized delivery systems, allow manufacturers to advance more customizable as well as lower-risk therapies.
Current Events and Their Impact on the Omeprazole Market
Current Event
Description and its Impact
Italy AIFA Introduces Note N01 for Proton Pump Inhibitors
Description: In early 2026, the Italian Medicines Agency (AIFA) approved and published Nota N01, a new regulatory guideline that updates conditions for prescribing Proton Pump Inhibitors (including omeprazole) under the Italian National Health Service. It officially repeals previous Notes and defines appropriate use criteria and limitations, especially around chronic prescriptions, to promote rational PPI utilization.
Impact: This policy directly affects market access and reimbursement for omeprazole in Italy, likely influencing prescribing behavior by encouraging more appropriate use and potentially reducing long‑term, non‑clinical prescriptions. It may prompt other regional regulators to consider similar prescription oversight measures for PPIs, affecting global demand dynamics.
Rising Import Prices and Tight Supply Dynamics in the U.S. Omeprazole Market
Description: In May 2026, U.S. omeprazole import prices strengthened due to expensive supply from Asian producers (including India and China) and limited offshore allocations. Quality audits caused slower batch releases, while elevated freight costs and lower production levels reduced export availability.
Impact: Higher landed costs and supply tightness can raise U.S. pricing pressure for both branded and generic omeprazole, squeezing margins for importers and potentially encouraging domestic production scaling or alternative supply sourcing. This may also slow generic volume growth if pricing becomes less competitive.
The rising prevalence of gastroesophageal reflux disease (GERD) continues to underpin a strong demand for omeprazole therapies. In the United States, approximately 20% of adults experience GERD symptoms weekly. This makes it one of the most commonly treated digestive conditions with proton pump inhibitors such as omeprazole.
The adoption of patient centric formulations including delayed release capsules, chewable tablets, and orally disintegrating films is improving adherence, convenience, and therapeutic outcomes, thereby encouraging a broader market uptake for the long term acid suppression.
The expansion of generic availability and supportive reimbursement frameworks is enhancing the accessibility and affordability, particularly in North America and Europe. For example, Medicare Part D in the United States includes coverage for prescription omeprazole, thereby allowing for the wider use amongst the chronic patients.
The combination therapies for Helicobacter pylori eradication using proton pump inhibitors like omeprazole are increasing therapeutic effectiveness and widening indications. The community studies indicate H. pylori infection remains prevalent in many populations, often above 40 percent in adults, which supports the ongoing use of omeprazole in eradication regimens.
The regional disease burden patterns are shifting with rising gastroesophageal disease rates in Asia Pacific. The community-based surveillance suggests symptomatic GERD in India is found in over 8 percent of adults, with higher prevalence in urban areas, while China epidemiological data shows a growing number of reflux cases, thereby highlighting expanding treatment demand in these markets.
Asia Pacific Dominates Owing to the Rising Disease Burden and Improved Access
The Asia Pacific region accounts for 37.5% of the market share in 2026. The region’s growth is owing to expanding populations, rising gastrointestinal disease incidence, and growing medical reimbursement infrastructure.
Real-world electronic medical record data tracking proton pump inhibitor (PPI) distribution across major clinical networks in India shows that omeprazole accounts for exactly 6.0% of overall gastrointestinal drug utilization patterns within specialized comorbidity treatment cohorts.
In June 2025, Torrent Pharmaceuticals acquired a controlling stake in J. B. Chemicals from KKR, merging the entities to strengthen its healthcare platform. Torrent manufactures omeprazole under the brand Omizac, enhancing chronic care offerings and international CDMO capabilities.
North America Omeprazole Market Trends
North America is expected to witness strong growth in Omeprazole Market over the forecast period. The region’s growth is owing to the high proton pump inhibitor use among older adults, broad GERD and acid-reflux treatment needs, and continued OTC access.
Official NCHS data indicates a strong recurring treatment base for acid-suppression therapies in North America, with proton pump inhibitor use reported among 16.9% of U.S. adults and 18.3% of Canadian adults aged 60–79. This reflects the sustained demand for omeprazole, particularly among older patients managing GERD, peptic ulcers, as well as the other acid-related gastrointestinal disorders.
In July 2023, RedHill Biopharma partnered with Phil Inc. to make Talicia (omeprazole magnesium, amoxicillin, and rifabutin) accessible to adults with Helicobacter pylori infection through the PhilRx Patient Access Platform, thereby enhancing the patient reach and treatment availability in the U.S.
Frequent Heartburn Prevalence and OTC Product Innovation is Accelerating the Omeprazole Market in United States
The U.S. market is growing as rising cases of frequent heartburn, GERD, as well as acid-related gastrointestinal disorders continue to propel the demand for proton pump inhibitor therapies.
In 2023, Omeprazole ranked among the top 10 most prescribed medications in the U.S., with around 45.3 million prescriptions dispensed to nearly 12.8 million patients.
Perrigo Company plc received U.S. FDA approval for Omeprazole Magnesium Delayed-Release Mini Capsules, 20 mg OTC. The product is designed as an over-the-counter therapy for frequent heartburn in adults.
China Omeprazole Market Trends
In China, the increasing prevalence of gastrointestinal disorders, rising awareness of acid-related health conditions, and expansion of hospital and clinical infrastructure are propelling growth in the Omeprazole Market.
Omeprazole sodium for injection received approval for the expanded indication of prevention of stress ulcer bleeding in critically ill patients, and it was incorporated into the 2023 National Reimbursement Drug List in China.
Joincare’s subsidiary Lizhu Pharmaceutical Factory received NMPA approval confirming that its injectable omeprazole sodium passed China’s drug consistency evaluation, strengthening product quality, domestic substitution, hospital use in ulcer bleeding and reflux cases, and the company’s future competitiveness.
Who are the Major Companies in Omeprazole Industry
Some of the major key players in Omeprazole Market are Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc, Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.
Key News
In May 2026, Bimeda launched GASTROBIM (omeprazole) in the U.S., the first FDA-approved bioequivalent to GastroGard for treating and preventing gastric ulcers in horses and foals aged four weeks and older. The apple-flavored formulation provides veterinarians and horse owners a clinically equivalent, high-quality alternative for managing Equine Gastric Ulcer Syndrome (EGUS).
In February 2026, Cumberland Pharmaceuticals Inc. launched U.S. promotion for Talicia, an FDA-approved oral capsule for treating Helicobacter pylori infection in adults. Talicia is the only all-in-one therapy combining omeprazole, amoxicillin, as well as rifabutin.
In May 2025, PL Developments (PLD) received the FDA approval for its Omeprazole Magnesium Tablet, comparable to Prilosec OTC. This makes PLD the only US-based manufacturer of OTC Omeprazole. This is strengthening its leadership in the complex pharmaceutical
In April 2025, Alkaloid launched the first patented liquid Omeprazole for pediatric GERD treatment and hosted the First International Conference on Modern Approaches to GERD Treatment in Zagreb, Croatia. The product provides a ready-to-use liquid formulation, thus improving administration for infants, toddlers, patients with swallowing difficulties, as well as elderly patients. This marks a substantial advancement in the patient centric therapy.
In August 2024, RedHill Biopharma Ltd. launched Talicia (omeprazole magnesium, amoxicillin, and rifabutin) in the United Arab Emirates. Talicia is the first low-dose rifabutin-containing all-in-one therapy approved for adults with Helicobacter pylori infection in the UAE, expanding RedHill’s global presence.
Market Report Scope
Omeprazole Market Report Coverage
Report Coverage
Details
Base Year:
2025
Market Size in 2026:
USD 7.4 Bn
Historical Data for:
2020 To 2024
Forecast Period:
2026 To 2033
Forecast Period 2026 to 2033 CAGR:
3.9%
2033 Value Projection:
USD 9.67 Bn
Geographies covered:
North America: U.S., Canada
Latin America: Brazil, Argentina, Mexico, Rest of Latin America
Europe: Germany, U.K., France, Spain, Italy, Russia, Rest of Europe
Asia Pacific: China, Japan, India, Australia, South Korea, ASEAN, Rest of Asia Pacific
Middle East: GCC Countries, Israel, Rest of Middle East
Africa: North Africa, Central Africa, South Africa
The Omeprazole Market is driven by growing medical need. Millions of patients suffer from gastroesophageal reflux disease, peptic ulcers, and other acid related disorders, many of which remain untreated or inadequately managed. This means the market is not growing because of trends it is growing because people still need treatment.
Omeprazole is one of the most prescribed proton pump inhibitors globally. The estimates show that in the United States alone, over 45 million prescriptions were filled in 2023. This represents a large recurring patient base and ongoing reliance on effective acid suppressive therapy.
The new formulations and delivery methods like delayed release tablets and injectable preparations are gaining substantial traction, with the clinical data showing that more than 90 percent of patients achieve symptomatic relief. This high efficacy and patient satisfaction further propel the growth in the Omeprazole Market, thereby encouraging wider adoption across both established as well as emerging healthcare markets.
Market Segmentation
By Dosage Form (Revenue, USD Bn, 2021-2033)
Capsule
Powder
Tablet
By Indication (Revenue, USD Bn, 2021-2033)
Duodenal Ulcer
Gastric Ulcer
Gastroesophageal Reflux Disease (GERD)
Erosive Esophagitis
Others
By Distribution Channel (Revenue, USD Bn, 2021-2033)
International Society for Pharmacoeconomics and Outcomes Research (ISPOR)
American Gastroenterological Association (AGA)
European Association for Gastroenterology, Endoscopy & Nutrition (EAGEN)
Others
Public Domain Sources
U.S. Food and Drug Administration (FDA)
European Medicines Agency (EMA)
World Health Organization (WHO) – Drug Information
Centers for Medicare & Medicaid Services (CMS)
National Institutes of Health (NIH)
National Health Service (NHS) Drug Tariff
Government health ministry portals
Others
Proprietary Elements
CMI Data Analytics Tool
Proprietary CMI Existing Repository of Information for the Last 10 Years
Share
Share
About Author
Vipul Patil is a dynamic management consultant with 6 years of dedicated experience in the pharmaceutical industry. Known for his analytical acumen and strategic insight, Vipul has successfully partnered with pharmaceutical companies to enhance operational efficiency, cross broader expansion, and navigate the complexities of distribution in markets with high revenue potential.
Missing comfort of reading report in your local language? Find your preferred language :
The Omeprazole Market is expected to reach USD 9.67 Billion in 2033.
Major players operating in the global Omeprazole Market include Astrazeneca Plc., Sandoz, Inc., Mylan N.V., Apotex, Inc., Dr. Reddy’s Laboratories, Inc., Impax Laboratories, Inc., Perrigo Company Plc, Santarus, Inc., Watson laboratories, Inc., and Lek Pharmaceuticals d.d.
The intense generic competition, concerns regarding long-term side effects (such as bone fractures and kidney disease), the availability of alternative proton pump inhibitors (PPIs), and strict regulatory compliance requirements are the key factors hampering growth of the market.
The rising global prevalence of gastrointestinal disorders (like GERD and peptic ulcers), increasing access to over-the-counter (OTC) medications, a growing geriatric population, and adoption of sedentary lifestyles is boosting the demand for Omeprazole.
The Omeprazole Market is anticipated to grow at a CAGR of 3.9% between 2026 and 2033
Among regions, North America is expected to account for a largest market share in the global Omeprazole Market over the forecast period.
